Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial

INTRODUCTION/AIMS: Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin. Casimersen is a phosphorodiamidate morpholino oligomer designed to bypass frameshift DMD mutations and produce internally truncated, yet functional, dystrophin protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Kathryn R., Kuntz, Nancy L., Koenig, Erica, East, Lilly, Upadhyay, Sameer, Han, Baoguang, Shieh, Perry B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290993/
https://www.ncbi.nlm.nih.gov/pubmed/34105177
http://dx.doi.org/10.1002/mus.27347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290993/
https://www.ncbi.nlm.nih.gov/pubmed/34105177
http://dx.doi.org/10.1002/mus.27347

Ejemplares similares